Retinopathy of prematurity: New developments are cause for hope January 17, 2017

1 post / 0 new
Dr Geeta
Retinopathy of prematurity: New developments are cause for hope January 17, 2017

In Western countries, more than 90% of premature infants even with severe ROP can expect a favorable outcome, while under-resourced areas lack trained staffing, functional equipment, and even a rudimentary understanding of ROP in its myriad forms. Without less expensive and more accessible treatments, ROP will continue to condemn too many infants to a life of severe visual impairment or blindness

One proposed solution is the use of telemedicine in areas in which trained examiners are not available. Dr. Michael F. Chiang, MD, of the Departments of Ophthalmology & Medical Informatics and Clinical Epidemiology, Casey Eye Institute, Oregon Health & Science University, Portland, OR, notes that recent developments in wide-angle retinal imaging, computing, and information technology have facilitated the implementation of major real-world ROP telemedicine programs in the United States and throughout the world.

According to Dr. Chiang, "The nature of ROP care is now being gradually transformed by some of these technologies. By evaluating other emerging imaging technologies, understanding their benefits and limitations, and gradually implementing them into practice when warranted, pediatric ophthalmologists will be able to enhance the care they provide to patients for a broader range of problems in the future."
ROP is traditionally treated using laser ablation of the abnormal blood vessels, but advancements have been made using vascular endothelial growth factor (VEGF) inhibitors. Helen A. Mintz-Hittner, MD, Department of Ophthalmology and Visual Science, University of Texas Health Science Center-Houston, McGovern Medical School, Houston, TX, shares her unique, sometimes controversial work on bevacizumab that has swept the country and changed the way many physicians treat advanced ROP. The treatment shows promise, however, delayed recurrence of ROP after bevacizumab treatments does occur (usually 5-10%). Dr. Mintz-Hittner emphasizes "the need for proper case selection (timing), careful injection (technique), and appropriate long-term follow-up (at least 65 weeks adjusted age) for parameters (outcomes)" to properly manage an ROP infant.

David K. Wallace, MD, MPH, of the Departments of Ophthalmology and Pediatrics, Duke University School of Medicine, Durham, NC, contributes a balanced review of several anti-VEGF drugs. He cautions, "we have a long way to go to have an evidence-based paradigm for anti-VEGF treatment. There are many unanswered questions about which drug, what dose, relative benefits, and possible side effects. Consequently, there are many opportunities for high-quality comparative studies that will shape our future treatment of premature infants and aid in reducing the burden of blindness from ROP."

"We are fortunate to have a community of scientists devoted to working on a leading cause of blindness in children," commented Journal of AAPOS Editor-in-Chief William V. Good, MD, The Smith-Kettlewell Eye Research Institute, San Francisco, CA. "Look how far we have come, thanks to the hard work of so many. It's time to consider the real possibility that this condition can be eliminated. When that happens, we will have achieved nothing short of a miracle."
Explore further: Children born prematurely face up to a 19 times greater risk of retinal detachment later in life
More information: Michael F. Chiang. Retinopathy of Prematurity, Journal of American Association for Pediatric Ophthalmology and Strabismus (2016). DOI: 10.1016/j.jaapos.2016.10.001

Read more at: https://medicalxpress.com/news/2017-01-retinopathy-prematurity.html#jCp

Image_forum: